Gain Therapeutics Inc
Gain Therapeutics Inc (GANX) Historical Volatility
GANX's 30 day historical volatility is 109.25%, in the 64th percentile of readings over the past year. This is an average percentile, meaning Gain Therapeutics Inc shares have moved roughly in line with their typical range. GANX's 30 day implied volatility sits at 468.56%, with an IV Rank of 99.60%, leaving IV 359.31 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking GANX historical volatility helps you see how much Gain Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GANX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GANX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GANX's 30 day historical volatility, or GANX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GANX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →